Press Releases

Read our latest announcements

Filter by year:

2016-12-01
Modus Therapeutics to present poster at 58th ASH Annual Meeting in San Diego

STOCKHOLM, SWEDEN – December 1, 2016. Modus Therapeutics AB, a clinical-stage drug development company focused on innovative treatments for patients with sickle cell disease (SCD), will present a poster at the 58th American Society of Hematology (ASH) Annual Meeting in San Diego on 4th December. The ASH Annual Meeting is a world-leading event in malignant […]

View Press Release
2016-11-15
Independent DSMB endorses inclusion of adolescents in ongoing clinical study with sevuparin in Sickle Cell Disease

STOCKHOLM – November 15, 2016.  Modus Therapeutics AB today announced that after a safety review by an independent Data Safety Monitoring Board, adolescents between the age of 12 and 18 will now be enrolled into its ongoing clinical study with sevuparin in Sickle Cell Disease (SCD). In addition, the Company has decided to increase the […]

View Press Release
2016-11-07
Modus Therapeutics announces two new U.S. patents for its candidate drug sevuparin

STOCKHOLM – November 7, 2016.  Modus Therapeutics AB, a clinical-stage drug development company focused on innovative treatments for patients with sickle-cell disease, today announced that it has been granted two patents in the U.S. covering its proprietary compound sevuparin. More specifically the two patents have been granted claims for the substance sevuparin per se and […]

View Press Release
2016-10-20
Dilaforette changes name to Modus Therapeutics and announces intention to conduct an Initial Public Offering

NOT FOR PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SWITZERLAND, SINGAPORE OR THE UNITED STATES.   STOCKHOLM – October 20, 2016.  Dilaforette Holding AB, a clinical-stage drug development company, today announced its name change to Modus Therapeutics Holding AB and its intention to […]

View Press Release
2016-06-19
Modus poster presented at EHA Congress

Modus Therapeutics’s submission is entitled: ‘Sevuparin Demonstrates Binding to Key Adhesion Receptors Involved in Pathogenesis of Sickle-Cell Disease’.

View Press Release
2016-02-16
Modus Therapeutics signs collaboration agreement with Arabian Gulf University (Bahrain) for Phase 2 clinical development of sevuparin for Sickle Cell Disease

Under the scope of the agreement, Modus Therapeutics and AGU’s collaboration will facilitate the development of Modus Therapeutics’s lead candidate, sevuparin, for patients with SCD.

View Press Release
2016-02-08
Modus Therapeutics appoints new VP of Development

Lena Jendberg joins Modus Therapeutics from Swedish Orphan Biovitrum AB (Sobi), where she was Global Program Director, Project & Portfolio Management and Strategic Operations from 2010.

View Press Release